Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit
January 05 2018 - 1:00AM
Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage
biopharmaceutical company specialising in developing novel
antibiotics, announced today that the Company will participate in
the following event:
Cantor Antibiotics SummitJanuary
17, 2018Omni Berkshire HotelNew York, NY USA
Graham Lumsden, Chief Executive Officer, will
participate in a panel discussion, “Catalysts to Look for in
2018.”
The Cantor Antibiotics Summit will bring
together leading antibiotic companies to discuss: what will drive
the uptake of these new products, novel ways to treat infections
and important catalysts to look forward to in 2018. The Summit will
consist of various panels, in addition to one-on-one and small
group meetings.
For further information please
contact:
Motif Bio plc |
info@motifbio.com |
Graham
Lumsden (Chief Executive Officer) |
|
|
|
Walbrook PR
Ltd. (UK FINANCIAL PR & IR) |
+44 (0) 20 7933 8780 / motifbio@walbrookpr.com |
Paul
McManus/Helen Cresswell/Lianne Cawthorne |
|
|
|
MC
Services AG (EUROPEAN IR) |
+49 (0)89 210 2280 |
Raimund
Gabriel |
raimund.gabriel@mc-services.eu |
|
|
The
Trout Group (US IR) |
+1 (646
)378-2963 |
Meggie
Purcell |
mpurcell@troutgroup.com |
|
|
Notes to Editors
About Motif BioMotif Bio plc (AIM:MTFB)
(NASDAQ:MTFB) is a clinical-stage biopharmaceutical company engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria,
including MRSA. The Company’s lead product candidate, iclaprim, is
being developed for high-risk MRSA patient populations. The first
proposed indication, and near-term commercial opportunity, is for
the treatment of ABSSSI, one of the most common bacterial
infections, with 3.6 million patients hospitalised annually in the
U.S. The Company believes that iclaprim may be suitable for
first-line empiric therapy in ABSSSI patients, especially those
with renal impairment, with or without diabetes. Unlike current
standard of care antibiotics, in clinical trials to date,
nephrotoxicity has not been observed with iclaprim and dosage
adjustment has not been required in patients with renal
impairment.
Iclaprim has an underutilised mechanism of
action compared to other antibiotics. Clinical and
microbiology data indicate iclaprim has a targeted Gram-positive
spectrum of activity, low propensity for resistance development,
fixed dose administration and favourable tolerability profile.
Additionally, data support that the inactive metabolites of
iclaprim clear through the kidneys. The Company also plans to
develop iclaprim for hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), as
there is a high unmet need for new therapies in this
indication. A Phase 2 trial was conducted to study iclaprim
in patients with HABP. Iclaprim has been studied in an animal model
of pulmonary MRSA infection which mimics the pathophysiology
observed in patients with cystic fibrosis. Iclaprim has been
granted orphan drug designation by the U.S. FDA for the treatment
of Staphylococcus aureus lung infections in patients with cystic
fibrosis
Iclaprim has received Qualified Infectious
Disease Product (QIDP) designation from the FDA together with Fast
Track status. Upon acceptance by the FDA of a New Drug Application
(NDA), iclaprim will receive Priority Review status and, if
approved as a New Chemical Entity, will be eligible for 10 years of
market exclusivity in the US from the date of first approval, under
the Generating Antibiotic Incentives Now Act (the GAIN Act). In
Europe, 10 years of data exclusivity is anticipated.
Forward-Looking Statements
This press release contains forward-looking
statements. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Motif
Bio’s actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Motif Bio
believes that these factors include, but are not limited to, (i)
the timing, progress and the results of clinical trials for Motif
Bio’s product candidates, (ii) the timing, scope or likelihood of
regulatory filings and approvals for Motif Bio’s product
candidates, (iii) Motif Bio’s ability to successfully commercialise
its product candidates, (iv) Motif Bio’s ability to effectively
market any product candidates that receive regulatory approval, (v)
Motif Bio’s commercialisation, marketing and manufacturing
capabilities and strategy, (vi) Motif Bio’s expectation regarding
the safety and efficacy of its product candidates, (vii) the
potential clinical utility and benefits of Motif Bio’s product
candidates, (viii) Motif Bio’s ability to advance its product
candidates through various stages of development, especially
through pivotal safety and efficacy trials, (ix) Motif Bio’s
estimates regarding the potential market opportunity for its
product candidates, and (x) the factors discussed in the section
entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form
20-F filed with the SEC on May 1, 2017, which is available on the
SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation
to update or revise any forward-looking statements.
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024